GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
GT Biopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$6.69−0.34 (-4.84%)
Close on Oct 19, 2026
- Market cap
- $259.71M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
GT Biopharma has not reported a dividend
No dividend per share appears in GT Biopharma's annual filings since fiscal 2010.